J&J, Bay­er agree to $775M pay­out to set­tle Xarel­to lit­i­ga­tion; Bio­gen launch­es $5B buy­back in the wake of a dis­as­ter; Hookipa pitch­es $86M IPO

→ Right on dead­line this morn­ing we learned that J&J and Bay­er have reached a deal to set­tle their out­stand­ing lit­i­ga­tion on Xarel­to with a lump $775 mil­lion set­tle­ment. The two com­pa­nies were ac­cused of fail­ing to warn pa­tients prop­er­ly of the bleed­ing risk as­so­ci­at­ed with the blood thin­ner. The le­gal war has been on­go­ing for 5 years.

→ With its share price beat­en down bru­tal­ly at the end of last week fol­low­ing the col­lapse of its Phase III Alzheimer’s work, a shak­en Bio­gen is coun­ter­ing its mis­for­tunes with a $5 bil­lion buy­back cam­paign.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA